At its recent capital markets event,  Boku  outlined how it intends to meet its medium-term growth targets. The combination of ongoing growth from existing merchants as they add new local payment connections, signing up new enterprise merchants, and layering on new money movement services is expected to drive a revenue CAGR of at least 20% in the medium term, in line with  Edison Group 's forecast to FY27. After a period of heavy investment in product and back office, moderat

ALG Newsletter - Shifting new business dynamics. Listed SA life assurers recently reported very strong 30 June 2025 results from an earnings and shareholder distribution point of view, but it came with a caveat. They reported much lower mass retail volumes and only modest growth for affluent retail. While the affluent space is mature and highly competitive, the weak mass retail production is almost all due to significant market share gains by  Capitec  Insurance. Reach to fin

Datatec Limited (JSE: DTC) (OTCQX: DTTLF)  has seen continuing strong financial performance in H126, with growing profitability in Westcon and Logicalis International and a considerable improvement in performance for Logicalis Latin America year-on-year. Reported and headline EPS are expected to be 21.0–23.0c, with the midpoint up 95% and 110%, respectively, versus H125. Now excluding share-based payments, underlying EPS of 18.0–20.0c is expected to be 33–48% higher year-on-y

Greggs ’ Q325 trading update shows improving trading as the period progressed, following the already-flagged negative effect of July’s hot weather. With a slight improvement to the outlook for cost inflation, management’s expectations for full year profit are unchanged. This is despite indications of lower new space growth than initially guided, due to phasing of new build opportunities. Management was clear that there is potential for significantly more than 3,000 stores, an

Baillie Gifford  US Growth Trust (USA) invests in exceptional US businesses with the potential to grow substantially faster than the market and deliver above-market returns. The company’s recent performance has been strong. The portfolio returned an impressive 31.6% in NAV terms and 37.6% on a share price basis in the year to 31 August 2025, well ahead of the benchmark return of 12.7%. However, USA’s managers are disappointed in its performance over three and five years, whic

Basilea Pharmaceutica  has secured a BARDA contract of up to $159m to advance ceftibuten-ledaborbactam etzadroxil, its recently in-licensed oral, Phase III-ready antibiotic for complicated urinary tract infections (cUTIs). The agreement replaces the original BARDA deal with the licensee Venatorx (October 2023) and provides $6m in committed near-term funding, with a further up to $153m in milestone-based payments, including support for the planned Phase III programme.  Edison

Metro Bank (UK) 's H1 results provided strong evidence of its strategy’s effectiveness. With momentum building, it has a firm base for further progress in FY25 and beyond. Profitability increased substantially in H125, and management confidently reaffirmed all previous guidance. This includes a mid- to upper-teens percentage return on tangible equity from 2027 as the transition to higher-return corporate, commercial and SME lending and specialist mortgage lending continues. F

LAMDA Development S.A.  Development’s agreed disposal of land to ION Group for €450m is a landmark in the long-term development of the Ellinikon project and, if it successfully completes the relevant due diligence process, will underpin the long-term value of the company’s post-Phase 1 (PP1) development plans.  Edison Group  value LAMDA’s existing mall and marina operations plus Phase 1 at around €12.30/share. In addition, investors can take further comfort in the potential v

Basilea Pharmaceutica ’s H125 results reflected strong sales traction, with revenues up 36.3% y-o-y to CHF104m, underpinned by 21.7% growth in royalties. A key strategic milestone was the US launch of Zevtera, diversifying Basilea’s revenue base and de-risking future sales. Post-period developments (initiation of the second Phase III trial for fosmanogepix and acquisition of a novel oral antibacterial) indicate growing pipeline momentum, with R&D support from BARDA. Full-year

Halyk Bank  delivered a strong 26.1% y-o-y increase in net profit to KZT253.6bn in Q225, leading to a healthy annualised return on equity (ROE) of 32.2% (up from 31.7% in Q224). Loan book growth moderated in H125, with gross loans to individuals and legal entities increasing by 4.3% and 1.4% versus end-2024, respectively. Management still guides to a solid FY25 net loan portfolio growth of 15–20%, slightly down from 17–22% guided previously, as retail loan growth expectations